Naltrexone/Bupropion + Placebo

ApprovedRecruiting
0 watching 0 views this week๐Ÿ”ฅ Hot
80
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Obesity; Drug

Conditions

Obesity; Drug, Obesity, Morbid

Trial Timeline

Jun 4, 2025 โ†’ Aug 1, 2028

About Naltrexone/Bupropion + Placebo

Naltrexone/Bupropion + Placebo is a approved stage product being developed by Bausch Health for Obesity; Drug. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06620562. Target conditions include Obesity; Drug, Obesity, Morbid.

Hype Score Breakdown

Clinical
30
Activity
20
Company
5
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT06620562ApprovedRecruiting

Competing Products

20 competing products in Obesity; Drug

See all competitors
ProductCompanyStageHype Score
MK0493MerckPhase 2
52
MK0557MerckPhase 3
77
AMG 786AmgenPhase 1
32
Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide PlaceboEli LillyPhase 2
52
TirzepatideEli LillyPhase 2
52
exenatide + PlaceboEli LillyApproved
85
BrenipatideEli LillyPhase 1
33
Orforglipron + PlaceboEli LillyPhase 3
77
TERN-601Terns PharmaceuticalsPhase 2
49
MBX 4291 + PlaceboMBX BiosciencesPhase 1
28
PG-102Rani TherapeuticsPhase 1
25
Orforglipron + PlaceboEli LillyPhase 1
33
Tirzepatide + PlaceboEli LillyPhase 3
77
Eloralintide + PlaceboEli LillyPhase 1
33
Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide PlaceboEli LillyPhase 2
52
LY3437943 + Midazolam + Warfarin + CaffeineEli LillyPhase 1
33
Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injectionSkye BiosciencePhase 2
44
TirzepatideEli LillyApproved
85
Adenosine + RegadenosonAstellas PharmaPre-clinical
23
Micafungin + MicafunginAstellas PharmaApproved
85